Given that both EGFR and PTGS2 (COX-2) pathways orchestrate to promote tumor initiation, progression, angiogenesis, and metastasis, it is conceivable that combined targeting to both PTGS2 (COX-2) and EGFR pathways will yield better clinical outcome in CRC prevention and treatment. Here, PTGS2 is linked to colorectal carcinoma.